US 12,091,415 B2
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Jayanthy Jayanth, Buffalo Grove, IL (US); Mohamed-Eslam F. Mohamed, Gurnee, IL (US); Ahmed A. Othman, Libertyville, IL (US); Patrick J. Marroum, Springfield, IL (US); Peter T. Mayer, Libertyville, IL (US); and Ben Klünder, Ludwigshafen (DE)
Assigned to AbbVie Inc., North Chicago, IL (US)
Filed by AbbVie Inc., North Chicago, IL (US)
Filed on Jun. 6, 2023, as Appl. No. 18/329,980.
Application 18/329,980 is a division of application No. 18/174,738, filed on Feb. 27, 2023, granted, now 11,780,847, issued on Oct. 10, 2023.
Application 18/174,738 is a continuation of application No. 17/902,690, filed on Sep. 2, 2022, abandoned.
Application 17/902,690 is a continuation of application No. 17/184,194, filed on Feb. 24, 2021, abandoned.
Application 17/184,194 is a continuation of application No. 16/656,237, filed on Oct. 17, 2019, abandoned.
Application 16/656,237 is a continuation of application No. 15/891,012, filed on Feb. 7, 2018, abandoned.
Application 15/891,012 is a continuation of application No. 15/295,561, filed on Oct. 17, 2016, abandoned.
Claims priority of provisional application 62/352,380, filed on Jun. 20, 2016.
Claims priority of provisional application 62/301,537, filed on Feb. 29, 2016.
Claims priority of provisional application 62/267,672, filed on Dec. 15, 2015.
Claims priority of provisional application 62/242,797, filed on Oct. 16, 2015.
Prior Publication US 2023/0331735 A1, Oct. 19, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 31/4985 (2006.01); A61K 47/02 (2006.01); A61K 47/12 (2006.01); A61K 47/38 (2006.01); C07D 487/04 (2006.01); C07D 487/14 (2006.01)
CPC C07D 487/14 (2013.01) [A61K 9/0053 (2013.01); A61K 31/4985 (2013.01); A61K 47/02 (2013.01); A61K 47/12 (2013.01); A61K 47/38 (2013.01); C07D 487/04 (2013.01); C07B 2200/13 (2013.01)] 3 Claims
 
1. An oral extended-release tablet comprising:
about 30 mg of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and at least one pharmaceutically acceptable excipient,
wherein:
a single administration of the tablet to healthy adult subjects under fasting conditions results in a mean AUCinf from about 453 ng·hours/mL to about 660 ng·hours/mL, and a mean Cmax from about 55 ng/mL to about 85 ng/mL, of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide.